63 related articles for article (PubMed ID: 8462896)
1. Immunoscintigraphy of colorectal cancer using 111In-labeled monoclonal antibody to mucin.
Sakahara H; Onodera H; Shirato M; Yao Z; Ohshio G; Kobayashi H; Hosono M; Yano S; Nakada H; Imamura M
Cancer Immunol Immunother; 1995 Sep; 41(3):157-61. PubMed ID: 7553684
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunodetection with 111In-labeled monoclonal antibody Nd2 in patients with pancreatic cancer.
Chung YS; Sawada T; Kondo Y; Hirayama K; Inui A; Yamashita Y; Nakata B; Okamura T; Ochi H; Ho JJ; Kim YS; Sowa M
Jpn J Cancer Res; 1997 Apr; 88(4):427-34. PubMed ID: 9197537
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01.
Prinssen HM; Molthoff CF; Verheijen RH; Broadhead TJ; Kenemans P; Roos JC; Davies Q; van Hof AC; Frier M; den Hollander W; Wilhelm AJ; Baker TS; Sopwith M; Symonds EM; Perkins AC
Cancer Immunol Immunother; 1998 Sep; 47(1):39-46. PubMed ID: 9755877
[TBL] [Abstract][Full Text] [Related]
4. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer.
Petronis JD; Regan F; Lin K
Clin Nucl Med; 1998 Oct; 23(10):672-7. PubMed ID: 9790041
[TBL] [Abstract][Full Text] [Related]
5. Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates.
Qu Z; Sharkey RM; Hansen HJ; Shih LB; Govindan SV; Shen J; Goldenberg DM; Leung SO
J Immunol Methods; 1998 Apr; 213(2):131-44. PubMed ID: 9692846
[TBL] [Abstract][Full Text] [Related]
6. Structure determination of N-linked oligosaccharides engineered at the CH1 domain of humanized LL2.
Qu Z; Sharkey RM; Hansen HJ; Goldenberg DM; Leung S
Glycobiology; 1997 Sep; 7(6):803-9. PubMed ID: 9376682
[TBL] [Abstract][Full Text] [Related]
7. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro.
Omelyanenko V; Kopecková P; Gentry C; Shiah JG; Kopecek J
J Drug Target; 1996; 3(5):357-73. PubMed ID: 8866655
[TBL] [Abstract][Full Text] [Related]
8. Preclinical testing of an anti-erbB-2 recombinant toxin.
King CR; Kasprzyk PG; Fischer PH; Bird RE; Turner NA
Breast Cancer Res Treat; 1996; 38(1):19-25. PubMed ID: 8825119
[TBL] [Abstract][Full Text] [Related]
9. Development of Follicle-Stimulating Hormone Receptor Binding Probes to Image Ovarian Xenografts.
Lee CW; Guo L; Matei D; Stantz K
J Biotechnol Biomater; 2015 Sep; 5(3):. PubMed ID: 26779384
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of Mab CC188 for ovarian cancer imaging.
Xu M; Rettig MP; Sudlow G; Wang B; Akers WJ; Cao D; Mutch DG; DiPersio JF; Achilefu S
Int J Cancer; 2012 Sep; 131(6):1351-9. PubMed ID: 22130973
[TBL] [Abstract][Full Text] [Related]
11. Imaging ovarian cancer and peritoneal metastases--current and emerging techniques.
Kyriazi S; Kaye SB; deSouza NM
Nat Rev Clin Oncol; 2010 Jul; 7(7):381-93. PubMed ID: 20386556
[TBL] [Abstract][Full Text] [Related]
12. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays.
Buist MR; Kenemans P; van Kamp GJ; Haisma HJ
Cancer Immunol Immunother; 1995 Jan; 40(1):24-30. PubMed ID: 7828165
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody imaging of colorectal and ovarian cancer.
Haseman MK
West J Med; 1994 Oct; 161(4):412. PubMed ID: 7817555
[No Abstract] [Full Text] [Related]
14. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
Surwit EA; Childers JM; Krag DN; Katterhagen JG; Gallion HH; Waggoner S; Mann WJ
Gynecol Oncol; 1993 Mar; 48(3):285-92. PubMed ID: 8462896
[TBL] [Abstract][Full Text] [Related]
15. Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma.
Abdel-Nabi HH; Doerr RJ
Targeted Diagn Ther; 1992; 6():73-88. PubMed ID: 1576351
[TBL] [Abstract][Full Text] [Related]
16. In-111 CYT-103 immunoscintigraphy in the imaging of ovarian carcinoma.
Neal CE; Baker MR; Hilgers RD; Fanning J; Burke RC; Snodgrass J; Cull RD
Clin Nucl Med; 1993 Jun; 18(6):472-6. PubMed ID: 8319398
[TBL] [Abstract][Full Text] [Related]
17. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT.
Collier BD; Abdel-Nabi H; Doerr RJ; Harwood SJ; Olsen J; Kaplan EH; Winzelberg GG; Grossman SJ; Krag DN; Mitchell EP
Radiology; 1992 Oct; 185(1):179-86. PubMed ID: 1523304
[TBL] [Abstract][Full Text] [Related]
18. In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer.
Doerr RJ; Herrera L; Abdel-Nabi H
Cancer; 1993 Jun; 71(12 Suppl):4241-7. PubMed ID: 8508386
[TBL] [Abstract][Full Text] [Related]
19. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates.
Maguire RT; Pascucci VL; Maroli AN; Gulfo JV
Cancer; 1993 Dec; 72(11 Suppl):3453-62. PubMed ID: 8242578
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
